Literature DB >> 18243727

Acquired factor VIII inhibitors in oncohematology: a systematic review.

Massimo Franchini1, Giovanni Targher, Franco Manzato, Giuseppe Lippi.   

Abstract

Acquired hemophilia A is an uncommon but potentially life-threatening hemorrhagic disorder caused by the onset of autoantibodies against coagulation factor VIII. Acquired hemophilia A is most frequently associated with autoimmune diseases, neoplasia, pregnancy and drug reactions but in approximately 50% of the cases no underlying disorder can be identified. A prompt diagnosis of this acquired bleeding disorder is essential for the appropriate management which is aimed to the control of hemorrhage and the suppression of inhibitor. Based on electronic and hand searches of the published literature, this systematic review examines the current knowledge on factor VIII autoantibodies associated with oncohematological disorders.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18243727     DOI: 10.1016/j.critrevonc.2007.12.004

Source DB:  PubMed          Journal:  Crit Rev Oncol Hematol        ISSN: 1040-8428            Impact factor:   6.312


  15 in total

1.  Acquired factor VIII haemophilia following influenza vaccination.

Authors:  Guillaume Moulis; Grégory Pugnet; Haleh Bagheri; Claire Courtellemont; Antoine Huart; Dominique Chauveau; Jacques Pourrat; Jean-Louis Montastruc
Journal:  Eur J Clin Pharmacol       Date:  2010-06-27       Impact factor: 2.953

Review 2.  Diagnosis, laboratory aspects and management of acquired hemophilia A.

Authors:  Vincenzo Toschi; Francesco Baudo
Journal:  Intern Emerg Med       Date:  2010-04-21       Impact factor: 3.397

3.  Management of acquired haemophilia bleed in the backdrop of multiple myeloma.

Authors:  Cecil Ross; Kevin Kuriakose; Ganesh Shreehari Aswath; Sitalakshmi Subramanian
Journal:  Indian J Hematol Blood Transfus       Date:  2013-05-15       Impact factor: 0.900

4.  Factor VIII-von Willebrand factor complex inhibits osteoclastogenesis and controls cell survival.

Authors:  Marc Baud'huin; Laurence Duplomb; Stéphane Téletchéa; Céline Charrier; Mike Maillasson; Marc Fouassier; Dominique Heymann
Journal:  J Biol Chem       Date:  2009-09-16       Impact factor: 5.157

Review 5.  Interventions for treating acute bleeding episodes in people with acquired hemophilia A.

Authors:  Yan Zeng; Ruiqing Zhou; Xin Duan; Dan Long; Songtao Yang
Journal:  Cochrane Database Syst Rev       Date:  2014-08-28

6.  Treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma presenting simultaneously with acquired hemophilia and warm autoimmune hemolytic anemia.

Authors:  Chelsea Williams; Christian Cable; Julia Choi
Journal:  Proc (Bayl Univ Med Cent)       Date:  2017-07

Review 7.  The anti-CD20 monoclonal antibody rituximab to treat acquired haemophilia A.

Authors:  Giovanni D'arena; Elvira Grandone; Matteo N D Di Minno; Pellegrino Musto; Giovanni Di Minno
Journal:  Blood Transfus       Date:  2015-09-03       Impact factor: 3.443

8.  Multiple myeloma presenting with acquired factor VIII inhibitor.

Authors:  Ismail Sari; Mehmet Ali Erkurt; Ahmet Ifran; Kursat Kaptan; Cengiz Beyan
Journal:  Int J Hematol       Date:  2009-06-24       Impact factor: 2.490

9.  Successful Long Term Eradication of Factor VIII Inhibitor in Patients with Acquired Haemophilia A in Saudi Arabia.

Authors:  Galila Zaher; Soheir Adam
Journal:  Mediterr J Hematol Infect Dis       Date:  2012-04-02       Impact factor: 2.576

10.  Rituximab for managing acquired hemophilia A in a case of chronic neutrophilic leukemia with the JAK2 kinase V617F mutation.

Authors:  Shinsaku Imashuku; Naoko Kudo; Kagekatsu Kubo; Katsuyasu Saigo; Nanako Okuno; Kaoru Tohyama
Journal:  J Blood Med       Date:  2012-12-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.